195 related articles for article (PubMed ID: 12355685)
1. Depression in multiple sclerosis associated with interferon beta-1a (Rebif).
Pandya R; Patten S
Can J Psychiatry; 2002 Sep; 47(7):686. PubMed ID: 12355685
[No Abstract] [Full Text] [Related]
2. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
3. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.
Rieckmann P; O'Connor P; Francis GS; Wetherill G; Alteri E
Drug Saf; 2004; 27(10):745-56. PubMed ID: 15350158
[TBL] [Abstract][Full Text] [Related]
4. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Salvatore E; Morra VB; Orefice G
Neurology; 2009 Sep; 73(13):1078; author reply 1078-9. PubMed ID: 19786703
[No Abstract] [Full Text] [Related]
5. Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis.
Guijarro C; Benito-León J; Bermejo-Pareja F
Neurol Sci; 2011 Apr; 32(2):309-11. PubMed ID: 20890624
[TBL] [Abstract][Full Text] [Related]
6. [The use of rebif in the Moscow Municipal Multiple Sclerosis Center].
Popova EV; Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):68-71. PubMed ID: 21916159
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
Murdoch D; Lyseng-Williamson KA
Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
[TBL] [Abstract][Full Text] [Related]
8. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J;
Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898
[TBL] [Abstract][Full Text] [Related]
9. [PRISMS study. Interferon beta-1a therapy in relapsing-remitting multiple sclerosis].
Limmroth V
Internist (Berl); 2001 Feb; 42(2):305-7. PubMed ID: 11244885
[No Abstract] [Full Text] [Related]
10. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
11. [Interferon beta1-a IM once weekly does not modify general psychological function in the first months after therapy in patients with relapsing-remitting multiple sclerosis].
Baldauf E; Gross M; Fleury MC; Gentin M; Souvignet V; Warter JM;
Rev Neurol (Paris); 2005 Dec; 161(12 Pt 1):1197-204. PubMed ID: 16340915
[TBL] [Abstract][Full Text] [Related]
12. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis.
Crispín JC; Díaz-Jouanen E
Lupus; 2005; 14(6):495-6. PubMed ID: 16038117
[No Abstract] [Full Text] [Related]
13. [PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis].
Hartung HP; Flachenecker P; Weilbach FX; Rieckmann P
Nervenarzt; 1999 Feb; 70(2):182-5. PubMed ID: 10098156
[No Abstract] [Full Text] [Related]
14. [Severe Raynaud's phenomenon associated with interferon-beta 1a and fluoxetine].
De Broucker T; Lhote F
Ann Med Interne (Paris); 2000 Sep; 151(5):424-5. PubMed ID: 11033481
[No Abstract] [Full Text] [Related]
15. Autoimmune hepatitis-like reaction developing in a patient treated with interferon-β1a.
Mishra A; Guindi M; Kandel G; Streutker CJ
Histopathology; 2015 Mar; 66(4):605-7. PubMed ID: 24796493
[No Abstract] [Full Text] [Related]
16. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
Rudick RA; Kappos L; Kinkel R; Clanet M; Phillips JT; Herndon RM; Sandrock AW; Munschauer FE
Mult Scler; 2011 Mar; 17(3):353-60. PubMed ID: 20965959
[TBL] [Abstract][Full Text] [Related]
17. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis.
Serarslan G; Okuyucu E; Melek I; Hakverdi S; Duman T
Mult Scler; 2008 Mar; 14(2):259-61. PubMed ID: 18337427
[TBL] [Abstract][Full Text] [Related]
18. [The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis].
Boĭko AN; Batysheva TT; Bykova OV; Davydovskaia MV; Demina TL; Lashch NIu; Nankina IA; Ovcharov VV; Popova EV; Popova NF; Boĭko OV; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):98-103. PubMed ID: 22677685
[TBL] [Abstract][Full Text] [Related]
19. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
Francis GS; Grumser Y; Alteri E; Micaleff A; O'Brien F; Alsop J; Stam Moraga M; Kaplowitz N
Drug Saf; 2003; 26(11):815-27. PubMed ID: 12908850
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.
Murdoch D; Lyseng-Williamson KA
BioDrugs; 2005; 19(5):323-5. PubMed ID: 16207073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
